The role of factor Xa inhibitors in venous thromboembolism treatment.

Marine Diterpenes: Molecular Modeling of Thrombin Inhibitors with Potential Biotechnological Application as an Antithrombotic. Mar Drugs (2017) 0.75

Pulmonary tuberculosis - An emerging risk factor for venous thromboembolism: A case series and review of literature. Lung India (2017) 0.75

Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. J Med Case Rep (2016) 0.75

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76

Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47

Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol (2005) 2.40

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol (2010) 1.98

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J (2010) 1.91

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol (2013) 1.69

DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost (2008) 1.60

Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs (2013) 1.49

Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos (2012) 1.48

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis (2011) 1.30

Edoxaban: a new oral direct factor xa inhibitor. Drugs (2011) 1.02

Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol (2010) 0.99

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol (2015) 0.92

Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm (2008) 0.89

Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis (2015) 0.88

Perspectives on factor Xa inhibition. Curr Med Chem (2001) 0.87

Inhibition of Factor Xa : a potential target for the development of new anticoagulants. Am J Cardiovasc Drugs (2005) 0.82